Now showing items 1-3 of 3
Introducing artificial intelligence tools into clinical and non-clinical workflows, Evidence from the NHS Breast Screening Programme of staff and general population perceptions of and trust in the use of AI in this context and the implications for further testing and implementation.
Background: The East Midlands Radiology Consortium (EMRAD) is a partnership of seven NHS trusts spread over 11 hospitals, covering more than five million patients in the East Midlands of England. In 2018, EMRAD formed a ...
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.
Purpose: Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ER+ breast cancer, but it has administration and pharmacokinetic limitations. Pharmacodynamic ...
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
(Clinical Cancer Research https://clincancerres.aacrjournals.org/content/26/7/1574.long, 2020-04)
Purpose: The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration to ...